Matthew K. Szot's most recent trade in Cadrenal Therapeutics Inc was a trade of 9,933 Common Stock done at an average price of $7.0 . Disclosure was reported to the exchange on Dec. 29, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Cadrenal Therapeutics Inc | Matthew K. Szot | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 6.97 per share. | 29 Dec 2025 | 9,933 | 0 | - | 7.0 | 69,233 | Common Stock |
| NAYA Biosciences | Matthew K. Szot | Director | Sale of securities on an exchange or to another person at price $ 1.50 per share. | 03 Dec 2025 | 4 | 3 | - | 1.5 | 6 | Common stock |
| NAYA Biosciences | Matthew K. Szot | Director | Other type of transaction at price $ 0.00 per share. | 03 Dec 2025 | 3 | 0 | - | 0 | Common stock | |
| SenesTech Inc | Matthew K. Szot | Director | Sale of securities on an exchange or to another person at price $ 3.00 per share. | 14 Nov 2025 | 1 | 0 (0%) | 0% | 3 | 3 | Common Stock |
| Cadrenal Therapeutics Inc | Matthew K. Szot | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 13.99 per share. | 24 Oct 2025 | 1,800 | 11,733 | - | 14.0 | 25,182 | Common Stock |
| Cadrenal Therapeutics Inc | Matthew K. Szot | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 13.99 per share. | 24 Oct 2025 | 1,800 | 9,933 | - | 14.0 | 25,182 | Common Stock |
| Cadrenal Therapeutics Inc | Matthew K. Szot | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 14.07 per share. | 09 Oct 2025 | 1,800 | 13,533 | - | 14.1 | 25,326 | Common Stock |
| Cadrenal Therapeutics Inc | Matthew K. Szot | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 13.99 per share. | 09 Oct 2025 | 1,693 | 15,333 | - | 14.0 | 23,685 | Common Stock |
| Cadrenal Therapeutics Inc | Matthew K. Szot | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 13.99 per share. | 06 Oct 2025 | 107 | 17,026 | - | 14.0 | 1,497 | Common Stock |
| Cadrenal Therapeutics Inc | Matthew K. Szot | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 13.99 per share. | 29 Sep 2025 | 1,700 | 17,133 | - | 14.0 | 23,783 | Common Stock |
| Cadrenal Therapeutics Inc | Matthew K. Szot | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 14.00 per share. | 29 Sep 2025 | 100 | 18,833 | - | 14 | 1,400 | Common Stock |
| Cadrenal Therapeutics Inc | Matthew K. Szot | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 14.05 per share. | 24 Sep 2025 | 10,900 | 18,933 | - | 14.1 | 153,182 | Common Stock |
| Cadrenal Therapeutics Inc | Matthew K. Szot | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 14.00 per share. | 24 Sep 2025 | 1,500 | 29,833 | - | 14.0 | 20,993 | Common Stock |
| Cadrenal Therapeutics Inc | Matthew K. Szot | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 14.00 per share. | 27 Aug 2025 | 1,600 | 31,733 | - | 14.0 | 22,392 | Common Stock |
| Cadrenal Therapeutics Inc | Matthew K. Szot | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 14.00 per share. | 27 Aug 2025 | 400 | 31,333 | - | 14 | 5,600 | Common Stock |
| NAYA Biosciences | Matthew K. Szot | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Aug 2025 | 45,000 | 45,164 | - | - | Stock Option (right to buy) | |
| Cadrenal Therapeutics Inc | Matthew K. Szot | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2025 | 50,000 | 50,000 | - | - | Stock Options | |
| SenesTech Inc | Matthew K. Szot | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Aug 2024 | 12,090 | 12,090 | - | - | Stock Option (right to buy) | |
| Cadrenal Therapeutics Inc | Matthew K. Szot | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2024 | 250,000 | 250,000 | - | - | Stock Options | |
| SenesTech Inc | Matthew K. Szot | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2023 | 39,402 | 39,402 | - | - | Stock Option (right to buy) | |
| NAYA Biosciences | Matthew K. Szot | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2023 | 85,000 | 85,000 | - | - | Stock Option (right to buy) | |
| Cadrenal Therapeutics Inc | Matthew K. Szot | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2023 | 50,000 | 500,000 | - | 0 | Common Stock | |
| SenesTech Inc | Matthew K. Szot | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2022 | 209,025 | 209,025 | - | - | Stock Option (right to buy) | |
| NAYA Biosciences | Matthew K. Szot | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2022 | 12,454 | 12,454 | - | - | Stock Option | |
| NAYA Biosciences | Matthew K. Szot | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2022 | 10,250 | 24,701 | - | 0 | Common Stock | |
| SW Seed Co | Matthew K. Szot | EVP Finance & Admin and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Oct 2021 | 80,000 | 80,000 | - | - | Stock option (right to buy) | |
| SW Seed Co | Matthew K. Szot | EVP Finance & Admin and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Oct 2021 | 7,490 | 138,140 (0%) | 0% | 0 | Common Stock | |
| SW Seed Co | Matthew K. Szot | EVP Finance & Admin and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.56 per share. | 01 Oct 2021 | 1,496 | 130,650 (0%) | 0% | 2.6 | 3,830 | Common Stock |
| SW Seed Co | Matthew K. Szot | EVP Finance & Admin and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.63 per share. | 01 Jul 2021 | 1,841 | 132,146 (0%) | 0% | 3.6 | 6,683 | Common Stock |
| SW Seed Co | Matthew K. Szot | EVP Finance & Admin and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2021 | 1,040 | 133,987 (0%) | 0% | - | Common Stock | |
| SW Seed Co | Matthew K. Szot | EVP Finance & Admin and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2021 | 1,040 | 0 | - | - | Restricted Stock Units | |
| SenesTech Inc | Matthew K. Szot | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2021 | 66,470 | 66,470 | - | - | Stock Option (right to buy) |